A Swiss-headquartered pharmaceutical group of companies has a five-year agreement for distribution.
Vergenix FG is based on company’s rhCollagen technology and is a wound-care product designed to treat acute and chronic hard-to-heal wounds.
Based on the deal, the company will deliver a portion of the order immediately and the remainder over the next six months.
“We are proud of the transformative potential of our recombinant human collagen platform technology that facilitates optimal treatment options for patients and remain open to additional collaborations that will bolster commercial infrastructure for Vergenix™ FG as well as support for our pipeline development efforts. At the same time, we continue to strategically focus on innovative applications of our rhCollagen in medical aesthetics and 3D Bioprinting of organs and tissues.” says CEO Yehiel Tal.